We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GE Healthcare’s Vivid Ultrasound Software Could Invite Hacking

GE Healthcare’s Vivid Ultrasound Software Could Invite Hacking

May 28, 2024

Devices in the GE Healthcare Vivid Ultrasound family contain 11 software vulnerabilities that could allow malicious invasion of these devices if a person had direct physical access to them, according to a security review conducted by Nozomi Networks Labs.

Nozomi particularly highlighted risks in the Vivid T9 cardiac imaging system and its pre-installed Common Service Desktop web application, and the EchoPAC software. If an attacker gained access to the device, the person could gain administrative privileges and potentially install ransomware and access and manipulate patient data.

Patches and mitigations for these vulnerabilities are available in the GE HealthCare Product Security Portal. GE, which participated in the review, said that existing mitigations and controls effectively reduce the risk “as far as possible,” and that the residual risk is “acceptable.”

To read the whole story, click here.

Related Topics

Devices Regulatory Affairs Submissions and Approvals

    Upcoming Events

    • 30May

      FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule

    • 13Jun

      FDA in 2024 and Beyond: What Election-Year Changes Mean for Your Business

    • 20Jun

      Inspection Readiness for EU GMP Annex 1 – Manufacture of Sterile Medicinal Products

    • 21Oct

      MAGI@home Clinical Research Conference 2024

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Pediatric Oncology Drug Studies Boosted by RACE Act, FDA Says

    • Two Additional Chinese Manufacturers’ Syringes Blocked From Entering US

    • Better FDA and USPTO Collaboration Can Stop Patent Thickets, Say Senators, Experts

    • Conservatives, Women, Rural Residents, Least Likely to Trust FDA, Survey Says

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing